RapidScreen RS-2000 helped radiologists spot small lung cancers

In the reader study that FDA reviewed for the RapidScreen RS-2000, 15 radiologists raised their area under the ROC curve for lung cancers from 0.8288 to 0.8654 with the system.

  • 2 an organization

    With the system, the radiologists' area under the ROC curve rose from 0.8288 to 0.8654 and their sensitivity from 71% to 78%.

Depth runs from 1, a convenience or time saved, to 5, a life or a livelihood preserved.

Status
Reported benefit.
Evidence

foundstudiedreportedclaimed

An independent regulatory document supports the benefit.

Compared with

The same radiologists reading the same films without the system. Measured.

Without the system
Area under the ROC curve 0.8288, sensitivity 71%
With it
Area under the ROC curve 0.8654, sensitivity 78%
The system’s part
The same 15 radiologists read every film without the system and later with it, so the change in performance is attributed to the system.
Limits
Not yet checked.
Costs and harms
Not yet checked.
Later
Not yet checked.

Download data Cite Suggest a correction

Benefit type
Improved Task Accuracy
System
RapidScreen RS-2000
Made by
Deus Technologies, LLC (listed as Riverain Medical Group in the FDA database)
Used by
Deus Technologies (reader study with 15 radiologists at Georgetown University Medical Center)
Where
Washington, D.C., United States
Stage
Tested in a laboratory
Date
, when the source was published
Kind
Aggregate result
Broad benefit
Identifying Objects, Actions, and Events
Collections
Scrutiny and findings
Last revised
31 October 2026

Sources

  1. Regulatory document, by authors with no tie to the system.

    U.S. Food and Drug Administration, Center for Devices and Radiological Health. Summary of Safety and Effectiveness Data for RapidScreen RS-2000 (P000041). Approved 2001-07-12. Scanned document without a text layer.

    A physician using the RS-2000 system can increase her or his ROC performance on chest x-ray radiographs for lung cancers 9.5-27.5 mm in size, which are usually early-stage lung cancers, of which only 15% are currently detected without computer aid (according to the American Cancer Society).

Details

AI system

Workflow

Each chest radiograph was digitized, and the system marked suspected nodules above a fixed likelihood threshold. Radiologists read each film without the system before they reviewed the marked image.

Follow-up

Conditions for replication

The physician completes an initial interpretation before consulting the marks. The patient belongs to the group in which the device was validated, adult male smokers aged 45 or older at high risk for cancer.

Entry details

Sector

Healthcare.

Purpose

Deus Technologies built the RapidScreen RS-2000 to mark regions of interest on frontal chest radiographs that could be early-stage lung cancer, for physicians to recheck after their own reading.

Not yet checked: model, release, provider, role, configuration, inputs and outputs, autonomy, human oversight, beneficiaries, reach, distribution and access, duration, every measurement question, every money question, ownership and control, dependencies, cross-border connections, geopolitical implications, replication attempts, availability, institutional decision, grounds, action and result, success criterion, every evidence question, observed or intended, alternative assessments, related entries, other identifiers, category mappings.

Cite this record

Peter H. Vartanian. (2026). RapidScreen RS-2000 helped radiologists spot small lung cancers (AIBD-0798). Artificial Intelligence Benefits Database, edition of 31 October 2026. https://petervartanian.xyz/aibd/records/AIBD-0798.html (archived at https://doi.org/10.7910/DVN/AADSII, version 4.0)

BibTeX Data Field definitions